Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.


Updates from The Motley Fool

Latest updates on Novartis from Fool.com.  The Fool has written over 600 articles on Novartis.
Did Novartis Overpay for AveXis?

$9.8 billion isn’t pocket change, but AveXis presents some huge potential opportunities down the ...

How Did Biogen Miss AveXis?

Biogen shareholders are probably not thrilled to see Novartis’ latest acquisition. What was Bioge...

What Novartis Bought in AveXis

Novartis’ $9.8 billion acquisition of AveXis signals some pretty exciting long-term focus in prom...



Stock Performance

View Interactive NVS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novartis.
Current Price: $85.90
Prev Close: $85.29
Open: $86.07
Bid: $85.88
Ask: $85.89
Day's Range: $85.79 - $86.32
52wk Range: $72.30 - $94.19
Volume: 1,315,782
Avg Vol 1,613,787
Market Cap: $201B
P/E (ttm): 26.00
EPS (ttm): $3.28
Div & Yield: $2.72 (2.9%)

Company Rating

What our community thinks about Novartis.
CAPS Rating 4 out of 5
 
1454 Outperform
47 Underperform
CAPS All Stars
 
302 Outperform
12 Underperform

How do you think Novartis will perform against the market?



You pick for Novartis is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Vas Narasimhan, CEO

93% Approve

Based on 94 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novartis.

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers